Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Enifer closes on €36M for proprietary mycoprotein

Finland-based mycoprotein company Enifer announced the completion of a €36 million (US$38.9 million) funding package comprising:

~ €15 million (US$16.2 million) in Series B funding led by the Finnish private equity fund Taaleri Bioindustry Fund I and follow-on investments from Nordic Foodtech VC, Voima Ventures, and Valio.

~ A €7 million (US$7.6 million) capital loan extended by the Finnish Climate Fund to support the company.

~ A €2 million (US$2.16 million) Climate and Environmental Loan provided by Finnvera.

~ And €12 million (US$13 million) in previously announced recycling and recuse investment grant funding from Business Finland.

Taken together, this funding will now allow Enifer to begin construction on a novel, food-grade mycoprotein factory in Kirkkonummi, Finland expected to cost €33 million (US$35.6 million). The facility, which will be the world's first commercial plant to produce a mycoprotein from sidestream raw materials, will have a capacity to produce up to 3,000 tons of Enifer's sustainable, fungi-based protein PEKILO® annually, or enough to cover the protein needs of 40,000 people for a year.

Read more at globalaginvesting.com

Publication date: